An Open-label, Single-dose, Single-centre Study, Investigating the Pharmacokinetics of BIA 2-093

• ClinicalTrials.gov Identifier: NCT02281422
• Recruitment Status: Completed
• First Posted: November 2, 2014
• Results First Posted: December 31, 2014
• Last Update Posted: December 31, 2014
• Sponsor: Bial - Portela C S.A.
• Information provided by (Responsible Party): Bial - Portela C S.A.

Study Description

Brief Summary:

Open-label, single-dose (BIA 2-093 800 mg tablet), single-centre study in five groups of subjects with various degrees of renal function based on creatinine clearance

Condition or disease	Intervention/treatment	Phase
Epilepsy	Drug: BIA 2-093	Phase 1

Detailed Description:

This was an open-label, single-dose (BIA 2-093 800 mg tablet), single-centre study in five groups of subjects with various degrees of renal function based on creatinine clearance (stages of renal function according to the Food and Drug Administration and the European Agency for the Evaluation of Medicinal Products Guidelines) for the evaluation of pharmacokinetics in patients with impaired renal function.

The trial commenced with Groups 1 and 2. An interim safety evaluation was conducted and, as there were no safety concerns, the trial continued with Groups 3 and 4. After another interim safety evaluation with the data from Groups 3 and 4, the trial commenced with Group 5.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 40 participants
• Allocation: Non-Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: An Open-label, Single-dose, Single-centre Study, Investigating the Pharmacokinetics of BIA 2-093 in Subjects With Various Degrees of Renal Impairment
• Study Start Date: March 2005
• Actual Primary Completion Date: June 2006
• Actual Study Completion Date: June 2006

Arms and Interventions

Arm	Intervention/treatment
Group 1 normal renal function; normal renal function (creatinine clearance > 80 mL/min)	Drug: BIA 2-093
Group 2 mild renal impairment; mild renal impairment (creatinine clearance 50-80 mL/min)	Drug: BIA 2-093
Group 3 moderate renal impairment; moderate renal impairment (creatinine clearance 30-50 mL/min)	Drug: BIA 2-093
Group 4 severe renal impairment; severe renal impairment (creatinine clearance <30 mL/min)	Drug: BIA 2-093
Group 5 end stage renal disease; end stage renal disease, requiring haemodialysis (ESRD)	Drug: BIA 2-093

Outcome Measures

Primary Outcome Measures :

1. Cmax - Peak Plasma Concentration [ Time Frame: pre-dose and 1, 2, 2.25, 2.5, 2.75, 3, 3.25, 3.5, 3.75, 4, 5, 7, 9, 12, 24, 48, 72 and 96 hours post-dose. ]
   BIA 2-194; BIA 2-195; Oxcarbazepine are BIA 2-093 metabolites
2. AUC(0-12h) - AUC From Time Zero to 12h [ Time Frame: pre-dose and 1, 2, 2.25, 2.5, 2.75, 3, 3.25, 3.5, 3.75, 4, 5, 7, 9, 12, 24, 48, 72 and 96 hours post-dose. ]

   BIA 2-194; BIA 2-195; Oxcarbazepine are BIA 2-093 metabolites

   AUC - area under the plasma concentration versus time curve

Secondary Outcome Measures :

1. Tmax (hr) - Time at Which Cmax Occurred [ Time Frame: pre-dose and 1, 2, 2.25, 2.5, 2.75, 3, 3.25, 3.5, 3.75, 4, 5, 7, 9, 12, 24, 48, 72 and 96 hours post-dose. ]

   BIA 2-194; BIA 2-195; Oxcarbazepine are BIA 2-093 metabolites

   Cmax - maximum observed plasma drug concentration

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Criteria

Inclusion Criteria:

• Males and females at least 18 years of age, with body mass not less than 50 kg.
• Female subjects had to be post-menopausal, surgically sterilized or using a reliable method of contraception.
• Subjects suffering from a chronic illness, other than hepatic impairment, had to have a stable condition, regarded by the investigator as unlikely to influence the outcome of the study.
• Renal failure, the extent of which, as measured by the creatinine clearance, resulted in recruitment to one of five renal function groups.
• Medical records indicating a stable serum creatinine (variation of not more than 30%), for at least 3 months prior to the screening visit (Groups 2 to 4 only), as determined by the clinical investigator. The sérum creatinine had to be stable to allow for an accurate determination of the creatinine clearance and therefore allowed for correct allocation to one of the renal function groups. Subjects who were recruited into Group 1 had normal renal function.

Exclusion Criteria:

• The receipt of any investigational drug within 30 days prior to this study.
• Clinically significant abnormal findings (as judged by the investigator) for the following parameters, except those consistent with findings in renal failure: haematology, biochemistry, clotting profile, urinalysis, vital signs or ECG screening tests.
• A history or laboratory evidence of hepatic impairment and/or disease. Owing to the metabolic pathway of BIA 2-093, any degree of hepatic impairment would have had a confounding effect on the PK analysis.
• Positive test for HIV-1 or HIV-2 Antibodies, Hepatitis B surface antigen and Hepatitis C Antibodies.

HIV positive patients, and patients with Hepatitis B and C, generally have a below average, and in some cases a markedly decreased, level of health owing to the nature of the respective infections and the natural course of the diseases, both of which are often complicated by an array of opportunistic illnesses. Their ill health would have been further worsened by the fact that the patients are invarious degrees of renal failure, which has its own, often debilitating, complications. If patients with HIV or Hepatitis B or C were included in the study, this could have led to statistical confusion when assessing the safety and tolerability parameters. This is because events reported by the patients, which may be a part of the spectrum of complaints in HIV positive patients and Hepatitis B and C patients, would have confounded the safety and tolerability analysis. Furthermore, Hepatitis B and C, which may cause an element of hepatic impairment, would have confounded the PK analysis due to the metabolic pathway of BIA 2-093. In addition, by administering the study medication to these subjects, any adverse events that might have occurred would have added to the discomfort of the patient.

• A history of any illness that, in the opinion of the Investigator and/or Sponsor, might have confounded the results.

Contacts and Locations

Locations

South Africa

Farmovs-Parexel

Bloemfontein, South Africa, 9301

Sponsors and Collaborators

Bial - Portela C S.A.

More Information

• Responsible Party: Bial - Portela C S.A.
• ClinicalTrials.gov Identifier: NCT02281422
• Other Study ID Numbers: BIA-2093-112
• First Posted: November 2, 2014
• Results First Posted: December 31, 2014
• Last Update Posted: December 31, 2014
• Last Verified: December 2014

Additional relevant MeSH terms:

Epilepsy; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Eslicarbazepine acetate; Anticonvulsants; Voltage-Gated Sodium Channel Blockers; Sodium Channel Blockers; Membrane Transport Modulators; Molecular Mechanisms of Pharmacological Action